The expression of COX-2 and EGFR in the majority of undifferentiated pancreatic carcinomas suggests that COX-2 and EGFR might represent targets for adjuvant therapy in anaplastic pancreatic cancer [10]. The gene discussed is EGFR; the disease is exocrine pancreatic carcinoma.